90 related articles for article (PubMed ID: 3102758)
1. Total bone uptake in management of metastatic carcinoma of the prostate.
Dann J; Castronovo FP; McKusick KA; Griffin PP; Strauss HW; Prout GR
J Urol; 1987 Mar; 137(3):444-8. PubMed ID: 3102758
[TBL] [Abstract][Full Text] [Related]
2. Quantitative bone scintigraphy and 24-hour whole-body counting of 99mTc-methylene diphosphonate in patients with prostatic carcinoma.
Sundkvist GM; Ahlgren L; Lilja B; Mattsson S
Nuklearmedizin; 1992 Oct; 31(5):178-81. PubMed ID: 1465355
[TBL] [Abstract][Full Text] [Related]
3. Enhanced uptake of 99Tcm-MDP in skeletal metastases from prostate cancer following initiation of hormone treatment: potential for increasing delivery of therapeutic agents.
Bushnell DL; Madsen M; Kahn D; Nathan M; Williams RD
Nucl Med Commun; 1999 Oct; 20(10):875-81. PubMed ID: 10528290
[TBL] [Abstract][Full Text] [Related]
4. Nuclear bone imaging in metastatic cancer of the prostate.
Pollen JJ; Gerber K; Ashburn WL; Schmidt JD
Cancer; 1981 Jun; 47(11):2585-94. PubMed ID: 6266636
[No Abstract] [Full Text] [Related]
5. Expanded 99mTc-methylene diphosphonate (MDP) bone scan.
Pollen JJ; Witztum K; Basarab R
Urology; 1984 Dec; 24(6):632-8. PubMed ID: 6239440
[TBL] [Abstract][Full Text] [Related]
6. The role of bone scanning in the assessment of prostatic carcinoma.
McGregor B; Tulloch AG; Quinlan MF; Lovegrove F
Br J Urol; 1978 May; 50(3):178-81. PubMed ID: 753456
[TBL] [Abstract][Full Text] [Related]
7. Distribution of skeletal metastases in prostatic and lung cancer. Mechanisms of skeletal metastases.
Morgan JW; Adcock KA; Donohue RE
Urology; 1990 Jul; 36(1):31-4. PubMed ID: 2368229
[TBL] [Abstract][Full Text] [Related]
8. Quantitative bone scintigraphy: usefulness in the survey of patients treated for bone metastasis of prostatic cancer.
Grob JC; Lallot C; Methlin G; Bollack C
Eur Urol; 1988; 15(3-4):193-5. PubMed ID: 3145888
[TBL] [Abstract][Full Text] [Related]
9. The 4 h/24 h 99mTc-MDP whole body retention: a new index of bone pathology.
Castronovo FP; McKusick KA; Strauss HW
Int J Rad Appl Instrum B; 1986; 13(6):599-602. PubMed ID: 3104238
[TBL] [Abstract][Full Text] [Related]
10. [Measurement of skeletal alkaline phosphatase in prostatic carcinoma. Preliminary report].
Casetta G; Gamba P; Piana P; Pecchio F; Tizzani A
Minerva Urol Nefrol; 1995 Mar; 47(1):9-12. PubMed ID: 7570264
[TBL] [Abstract][Full Text] [Related]
11. [Whole-body retention of 99mTc-methylene diphosphonate in skeletal diseases].
Zorn-Bopp E; Büll U; Münzing W; Lang P; Moser EA
Nuklearmedizin; 1983 Feb; 22(1):24-30. PubMed ID: 6223277
[TBL] [Abstract][Full Text] [Related]
12. Analytic Validation of the Automated Bone Scan Index as an Imaging Biomarker to Standardize Quantitative Changes in Bone Scans of Patients with Metastatic Prostate Cancer.
Anand A; Morris MJ; Kaboteh R; Båth L; Sadik M; Gjertsson P; Lomsky M; Edenbrandt L; Minarik D; Bjartell A
J Nucl Med; 2016 Jan; 57(1):41-5. PubMed ID: 26315832
[TBL] [Abstract][Full Text] [Related]
13. Alendronate does not interfere with 99mTc-methylene diphosphonate bone scanning.
Carrasquillo JA; Whatley M; Dyer V; Figg WD; Dahut W
J Nucl Med; 2001 Sep; 42(9):1359-63. PubMed ID: 11535725
[TBL] [Abstract][Full Text] [Related]
14. Computerized bone scan. A potentially useful technique to measure response in prostatic carcinoma.
Drelichman A; Decker DA; Al-Sarraf M; Vaitkevicius VK; Muz J
Cancer; 1984 Mar; 53(5):1061-5. PubMed ID: 6229325
[TBL] [Abstract][Full Text] [Related]
15. Serum osteocalcin measurements in prostate carcinoma patients with skeletal deposits shown by bone scintigram: comparison with serum PSA/PAP measurements.
Shih WJ; Wierzbinski B; Collins J; Magoun S; Chen IW; Ryo UY
J Nucl Med; 1990 Sep; 31(9):1486-9. PubMed ID: 1697617
[TBL] [Abstract][Full Text] [Related]
16. Metabolic activity in bone metastases of breast and prostate cancer were similar as studied by
Pietrzak A; Czepczynski R; Wierzchoslawska E; Cholewinski W
Hell J Nucl Med; 2017; 20(3):237-240. PubMed ID: 29177262
[TBL] [Abstract][Full Text] [Related]
17. Bone scan as a stratification variable in advanced prostate cancer.
Knudson G; Grinis G; Lopez-Majano V; Sansi P; Targonski P; Rubenstein M; Sharifi R; Guinan P
Cancer; 1991 Jul; 68(2):316-20. PubMed ID: 2070330
[TBL] [Abstract][Full Text] [Related]
18. The flare phenomenon on radionuclide bone scan in metastatic prostate cancer.
Pollen JJ; Witztum KF; Ashburn WL
AJR Am J Roentgenol; 1984 Apr; 142(4):773-6. PubMed ID: 6230903
[TBL] [Abstract][Full Text] [Related]
19. High false negative rate of Tc-99m MDP whole-body bone scintigraphy in detecting skeletal metastases for patients with hepatoma.
Chen CY; Wu K; Lin WH; Lan TY; Wang SY; Sun JS; Weng PW; Yen RF; Yang RS
J Formos Med Assoc; 2012 Mar; 111(3):140-6. PubMed ID: 22423667
[TBL] [Abstract][Full Text] [Related]
20. [Bone scintigraphy and rhenium radioisotope management in the course of metastatic prostatic cancer].
Ostwald E; Sabri O; Cremerius U; Jakse G; Büll U
Nuklearmedizin; 1999; 38(7):302-5. PubMed ID: 10599071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
